NDA 215244 · Stealth Biotheraps
Forzinity
Elamipretide Hydrochloride · Subcutaneous
NovelAccelerated approvalPriority reviewOrphanCDER novel approval, Sep 19, 2025: To improve muscle strength in patients with Barth syndrome weighing at least 30 kg
Last checked: Nov 20, 2026Latest source record: Sep 19, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2025
Sep 19, 2025
Approved uses
1
Original approval plus efficacy supplements
Registered trials
19
3 Phase 3, 2 recruiting
FAERS reports
2
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 6, 2026.
FORZINITY is indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. This indication is approved under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. FORZINITY™ is a mitochondrial cardiolipin binder indicated to improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg. ( 1 ) This indication is approved under accelerated approval based on an improvement in knee extensor muscle strength, an intermediate clinical endpoint. ( 14 ) Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).
Mechanism: FORZINITY is a mitochondrial cardiolipin binder that localizes to the inner mitochondrial membrane and improves mitochondrial morphology and function.
Therapeutic areas: Rare and genetic disease
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 19, 2025 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalOrphanLabelLetterReview
1 products under this application
- FORZINITY · ELAMIPRETIDE HYDROCHLORIDE EQ 280MG BASE/3.5ML (EQ 80MG BASE/ML) · SOLUTION, SUBCUTANEOUS · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Elamipretide" as an intervention, any sponsor and status, largest first.
- ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)Pivotal-lookingActive, not recruiting
Stealth BioTherapeutics Inc.Industry
NCT06373731 · 313 participants · Start May 30, 2024 · Primary completion Aug 2027
Drug: Elamipretide; Placebo · For: Age Related Macular Degeneration (ARMD)
Sites: Phoenix, Arizona; Sun City, Arizona; Huntington Beach, California · 53 sites in all
- A Phase 2 Study to Evaluate the Cardiac and Renal Effects of Short Term Treatment With Elamipretide in Patients Hospitalized With Congestion Due to Heart FailurePivotal-lookingCompleted
Stealth BioTherapeutics Inc.Industry
NCT02914665 · 308 participants · Start Oct 20, 2016 · Primary completion Nov 27, 2017
Drug: elamipretide; Placebo · For: Heart Failure
Sites: Aalst, Belgium; Antwerp, Belgium; Dimitrovgrad, Bulgaria · 46 sites in all
- Evaluation of Myocardial Effects of MTP-131 for Reducing Reperfusion Injury in Patients With Acute Coronary EventsPivotal-lookingCompleted
Stealth BioTherapeutics Inc.Industry
NCT01572909 · 300 participants · Start Apr 2012 · Primary completion Nov 2014
Drug: Bendavia (MTP-131); Placebo · For: Reperfusion Injury; STEMI
Sites: Port Orange, Florida; Detroit, Michigan; Omaha, Nebraska · 30 sites in all
- Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)Pivotal-lookingCompleted
Stealth BioTherapeutics Inc.Industry
NCT05162768 · 102 participants · Start Apr 29, 2022 · Primary completion Sep 30, 2024
Drug: Elamipretide; Placebo · For: Mitochondrial Myopathies; Mitochondrial Pathology; Mitochondrial DNA Mutation and 5 more
Sites: San Diego, California; Atlanta, Georgia; Boston, Massachusetts · 32 sites in all
Stealth BioTherapeutics Inc.Industry
NCT02788747 · 71 participants · Start Jun 2016 · Primary completion Sep 2017
Drug: 4 mg elamipretide; 40 mg elamipretide and 1 more · For: Heart Failure
Sites: Bergamo, Italy; Brescia, Italy; Cagliari, Italy · 15 sites in all
Stealth BioTherapeutics Inc.Industry
NCT07531251 · 48 participants (planned) · Start Jul 2, 2026 · Primary completion Sep 30, 2029
Drug: Elamipretide; Placebo · For: Barth Syndrome
Sites: Needham, Massachusetts; Westmead, Australia; Calgary, Canada · 4 sites in all
Stealth BioTherapeutics Inc.Industry
NCT02814097 · 46 participants · Start Sep 2, 2016 · Primary completion May 4, 2017
Drug: elamipretide; Placebo · For: Chronic Heart Failure
Sites: Berlin, Germany; Belgrade, Serbia; Kamenitz, Serbia · 9 sites in all
- A Phase 2 Study to Evaluate the Impact of MTP-131 (Bendavia™) on Skeletal Muscle Function in ElderlyCompleted
Stealth BioTherapeutics Inc.Industry
NCT02245620 · 41 participants · Start Jan 15, 2015 · Primary completion Jul 6, 2016
Drug: Elamipretide; Placebo · For: Skeletal Muscle Mitochondrial Dysfunction in the Elderly
Sites: Seattle, Washington
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- injection site reaction1
- off label use1
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2026 | 2 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.
Karaa A, Bertini E, Carelli V, et al. · Neurology 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.
Thompson WR, Manuel R, Abbruscato A, et al. · Genet Med 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.
Karaa A, Bertini E, Carelli V, et al. · Orphanet J Rare Dis 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.
Van den Eynde J, Chinni B, Vernon H, et al. · Orphanet J Rare Dis 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction.
Hortmann M, Robinson S, Mohr M, et al. · Eur Heart J Acute Cardiovasc Care 2019 · Clinical Trial, Phase II, Comparative Study
- Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.
Hornby B, Thompson WR, Almuqbil M, et al. · Orphanet J Rare Dis 2022 · Clinical Trial, Phase III, Observational Study
Sponsor: Stealth Biotheraps
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.